stoxline Quote Chart Rank Option Currency Glossary
  
AC Immune SA (ACIU)
1.69  -0.005 (-0.29%)    05-23 16:00
Open: 1.7
High: 1.72
Volume: 67,631
  
Pre. Close: 1.695
Low: 1.64
Market Cap: 167(M)
Technical analysis
2025-05-23 4:45:44 PM
Short term     
Mid term     
Targets 6-month :  2.1 1-year :  2.45
Resists First :  1.79 Second :  2.1
Pivot price 1.65
Supports First :  1.58 Second :  1.45
MAs MA(5) :  1.7 MA(20) :  1.66
MA(100) :  2.18 MA(250) :  2.95
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  58 D(3) :  64.6
RSI RSI(14): 50.1
52-week High :  4.97 Low :  1.42
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ACIU ] has closed below upper band by 37.0%. Bollinger Bands are 40.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.72 - 1.73 1.73 - 1.74
Low: 1.62 - 1.63 1.63 - 1.64
Close: 1.68 - 1.69 1.69 - 1.7
Company Description

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Headline News

Wed, 21 May 2025
Individual investors among AC Immune SA's (NASDAQ:ACIU) largest shareholders, saw gain in holdings value after stock jumped 11% last week - simplywall.st

Mon, 19 May 2025
AC Immune SA Announces Board Changes Ahead of June 2025 AGM - TipRanks

Wed, 30 Apr 2025
AC Immune Reports Q1 2025 Financial Results - TipRanks

Wed, 30 Apr 2025
AC Immune: Q1 Earnings Snapshot - San Antonio Express-News

Wed, 30 Apr 2025
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - marketscreener.com

Wed, 30 Apr 2025
AC Immune Q1 Results: Breakthrough in Parkinson's Treatment Shows Promise, Cash Runway Extended to 2027 - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 100 (M)
Held by Insiders 4.018e+007 (%)
Held by Institutions 38 (%)
Shares Short 1,350 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -5.022e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -184.1 %
Operating Margin -1 %
Return on Assets (ttm) 956.5 %
Return on Equity (ttm) -17.1 %
Qtrly Rev. Growth 2.83e+007 %
Gross Profit (p.s.) 0
Sales Per Share -26.86
EBITDA (p.s.) -2.16173e+007
Qtrly Earnings Growth -0.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 46 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.07
Price to Cash Flow 2.91
Stock Dividends
Dividend 0
Forward Dividend 1.45e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android